» Articles » PMID: 29688466

Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part II

Overview
Specialty Gastroenterology
Date 2018 Apr 25
PMID 29688466
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There has been burgeoning interest in quality of life (QoL) in inflammatory bowel disease (IBD) in recent decades, with hundreds of studies each year now assessing this outcome. This paper is part 2 of a systematic review evaluating 5 key QoL comparisons within IBD states and relative to others without IBD. Part 1 examined QoL comparing IBD and a healthy/general population and other medically ill groups. Part 2, presented here, examines within-disease comparisons of active/inactive disease, Ulcerative colitis (UC) / Crohn's disease (CD), and change in QoL over time. Outcomes using generic versus IBD-specific QoL measures were also examined.

Methods: Adult and pediatric studies were identified through systematic searches of 7 databases from the 1940s (where available) to October 2015.

Results: Of 6173 abstracts identified, 466 were selected for final review based on controlled design and validated measurement, of which 83 unique studies (75 adult, 8 pediatric) addressed the within-disease comparisons. The pooled mean QoL scores were significantly lower in active versus inactive IBD (n = 26) and for those with CD versus UC (n = 37), consistent across IBD-specific and generic QoL measures, for almost all comparisons. There was significant improvement in QoL over time (n = 37). Study quality was generally low to moderate. The most common measures of QoL were the disease-specific Inflammatory Bowel Disease Questionnaire and generic 36-Item Short Form Survey (SF-36) (adults) and the IBD-specific IMPACT (children).

Conclusions: For adults in particular, there was strong confirmation that QoL is poorer during active disease and may be poorer for those with CD. The finding that QoL can improve over time may be encouraging for individuals with this chronic disease.

Citing Articles

Patients With Experience of Hospitalization for Acute Severe Ulcerative Colitis Prefer Inpatient to Home-Based Care.

Mohamedrashed M, Yogakanthi S, Chauhan A, Lucas S, Garg M J Patient Exp. 2025; 12:23743735241301918.

PMID: 40007856 PMC: 11851743. DOI: 10.1177/23743735241301918.


[Position paper of the Society for Paediatric Gastroenterology and Nutrition (GPGE) on the off-label use of biologics and signal inhibitors in children and adolescents with IBD that have already been approved for adults].

Dabritz J, Classen M, Krohn K, Krahl A, Buderus S, Lainka E Z Gastroenterol. 2025; 63(3):255-268.

PMID: 39961333 PMC: 11893210. DOI: 10.1055/a-2474-3104.


Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases - A meta-analysis of randomized controlled trials.

Falcon B, de Mello Guimaraes T, Halpern G, Gomes C, de Mello Guimaraes T Indian J Gastroenterol. 2025; .

PMID: 39921836 DOI: 10.1007/s12664-024-01720-0.


Sexual and reproductive health considerations in the care of young adults with inflammatory bowel disease: A multidisciplinary conversation.

Reed S, Bugwadia A, Dave S, Wilson H, Ramesh P, Michel H Health Care Transit. 2024; 2:100033.

PMID: 39712618 PMC: 11658044. DOI: 10.1016/j.hctj.2023.100033.


Using Participatory Narrative Inquiry to Assess Experiences and Self-Experimentation with Diet Interventions in Inflammatory Bowel Disease Patients.

Hos C, Tebbens M, Bezema T, Bosch J, Kraneveld A, Spooren C Nutrients. 2024; 16(23).

PMID: 39683421 PMC: 11643754. DOI: 10.3390/nu16234027.